Skip to main content
WHANIN PHARM CO.,LTD logo

WHANIN PHARM CO.,LTD — Investor Relations & Filings

Ticker · 016580 ISIN · KR7016580003 KO Manufacturing
Open in API
Filings indexed 178 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 016580

About WHANIN PHARM CO.,LTD

https://www.whanin.com/?lang=eng

WHANIN PHARM CO.,LTD. is a pharmaceutical company that develops, manufactures, and sells a range of therapeutic products. The company specializes in medications for the Central Nervous System (CNS), with a particular focus on neuropsychiatric treatments such as anti-psychotics and CNS stimulants. In addition to its core CNS portfolio, Whanin Pharm's product line includes pharmaceuticals for the cardiovascular and gastrointestinal systems, antibiotics, and vitamin supplements. The company also provides development and manufacturing services for finished drug formulations.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” covering the quarter from 2026.01.01 to 2026.03.31 and contains a full table of contents with actual financial statements, notes, management discussion and analysis, audit opinion, and other detailed sections. It is therefore a complete interim/quarterly report, not merely an announcement or a transcript. Accordingly, it is classified as an Interim / Quarterly Report (IR). Q1 2026
2026-05-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 92% confidence The document is a detailed ‘주식등의 대량보유상황보고서(일반)’ (Report on large shareholdings) filed under Korean capital markets law, disclosing changes in substantial share ownership exceeding thresholds. This matches a Major Shareholding Notification rather than board changes, earnings, or other filings.
2026-05-11 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 94% confidence The document is a Korean ‘공정공시’ disclosure of preliminary consolidated financial results for Q1 2026 (Jan–Mar), comparing to prior quarter and year-ago quarter. It provides key revenue and profit figures without full financial statements or narrative commentary, and serves as the initial announcement of quarterly results. This matches the Earnings Release category (ER) rather than a full Interim Report (IR) or investor presentation (IP). Q1 2026
2026-04-27 Korean
기업가치제고계획(자율공시)
Regulatory Filings Classification · 65% confidence The document is a voluntary disclosure (“자율공시”) by Hwanin Pharmaceutical outlining its corporate value enhancement plan for 2026, including strategic objectives, dividend metrics under tax law, and planning details. It is not an AGM presentation, earnings release, dividend notice, financing update, or any other specific category defined. It is a general regulatory announcement of plans and thus best fits the fallback “Regulatory Filings” category (RNS).
2026-03-23 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the appointment, dismissal, or resignation of an outside director (사외이사). This type of corporate governance disclosure specifically pertains to changes in the board of directors, which falls under the 'Board/Management Information' category.
2026-03-20 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과) for Hwanin Pharmaceutical. It details the approval of financial statements, dividend declarations, director appointments, and voting results for specific agenda items. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), as it provides the outcome of shareholder votes at the AGM.
2026-03-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.